These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 15844071

  • 1. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T, Tuberculosis Trials Consortium.
    Clin Infect Dis; 2005 May 15; 40(10):1481-91. PubMed ID: 15844071
    [Abstract] [Full Text] [Related]

  • 2. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J, Munsiff SS, Driver CR, Sackoff J.
    Clin Infect Dis; 2005 Jul 01; 41(1):83-91. PubMed ID: 15937767
    [Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA, Weiner MH, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, Peloquin CA, Tuberculosis Trials Consortium.
    Pharmacotherapy; 2007 Jun 01; 27(6):793-800. PubMed ID: 17542762
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA.
    Clin Infect Dis; 2009 Nov 01; 49(9):1305-11. PubMed ID: 19807276
    [Abstract] [Full Text] [Related]

  • 5. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
    Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, Cronin W, Hooper N, Bishai W, Sterling TR.
    Clin Infect Dis; 2004 Mar 01; 38(5):731-6. PubMed ID: 14986259
    [Abstract] [Full Text] [Related]

  • 6. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER, Joseph K.
    Clin Infect Dis; 2009 May 15; 48(10):1471-4. PubMed ID: 19368504
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
    Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE.
    Pharmacotherapy; 2009 May 15; 29(5):503-10. PubMed ID: 19397460
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z, Tuberculosis Trials Consortium.
    Clin Infect Dis; 2005 Nov 01; 41(9):1343-9. PubMed ID: 16206114
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
    Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, Weiner M, El-Sadr W, Tuberculosis Trials Consortium.
    Am J Respir Crit Care Med; 2006 Feb 01; 173(3):350-6. PubMed ID: 16109981
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Does AIDS impair the absorption of antituberculosis agents?
    Taylor B, Smith PJ.
    Int J Tuberc Lung Dis; 1998 Aug 01; 2(8):670-5. PubMed ID: 9712282
    [Abstract] [Full Text] [Related]

  • 13. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S, Deivanayagam CN, Rajasekaran S, Venkatesan P, Padmapriyadarsini C, Menon PA, Ponnuraja C, Dilip M.
    Natl Med J India; 2008 Aug 01; 21(1):3-8. PubMed ID: 18472696
    [Abstract] [Full Text] [Related]

  • 14. Drugs for tuberculosis.
    Treat Guidel Med Lett; 2004 Dec 01; 2(28):83-8. PubMed ID: 15557876
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
    Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ.
    Clin Infect Dis; 2007 Nov 15; 45(10):1290-5. PubMed ID: 17968823
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Acquired rifamycin resistance: pharmacology and biology.
    Wallis RS, Weyer K, Fourie PB.
    Expert Rev Anti Infect Ther; 2008 Apr 15; 6(2):223-30. PubMed ID: 18380604
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.